Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaher Corporation (DHR) vs Invesco Preferred ETF (PGX) Price & Performance

Danaher CorporationTrade
Invesco Preferred ETFTrade

Price performance (Past 24H)

Key statistics

Danaher Corporation vs Invesco Preferred ETF — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while Invesco Preferred ETF trades at $10.03 (market cap $3.60B). The key difference: Danaher Corporation is far larger — about 42.5× Invesco Preferred ETF's market cap, and Danaher Corporation pays a 0.74% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Invesco Preferred ETF for 94 Days on average.

DHRPGX
Market Cap
$152.87B$3.60B
Volume
5,228,6985,986,026
Sector
Health—
52-Week High
$242.05$11.61
52-Week Low
$161.91$9.97
Typical Hold Time
69 Days94 Days
Enterprise Value
$175.08B—
Dividend Yield
0.74%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaher Corporation

Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.

The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.

Invesco Preferred ETF

PGX trades at $9.97, down 0.89% today, with technical indicators showing a bearish trend from moving averages but oversold signals from the RSI. The stock faces pressure amid mixed sentiment, with key support and resistance levels clustered around $10. Recent corporate actions include scheduled dividends for July and September 2026, but fundamental data such as P/E and profitability metrics are unavailable for analysis.

The outlook for PGX is cautious due to the bearish technical setup and lack of current fundamental visibility. Risks include potential volatility near the $10 level and dependence on future financial disclosures to assess valuation. Investment opportunity hinges on upcoming earnings reports clarifying growth and margins, while sentiment remains divided amid limited recent news coverage.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DHR
18% Buy82% Sell
Avg holding period · 69 Days
PGX
100% Buy0% Sell
Avg holding period · 94 Days

Top news

Latest headlines on both assets

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR →

About Invesco Preferred ETF

The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.

Read more on PGX →